Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06926920 · ClinicalTrials.gov registry record · Phase 1

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

A Phase 1 study of Triple Negative Breast Cancer, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
16
Study locations

NCT06926920 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 100 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (59% lower). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06926920, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
16
Study locations

Study Summary

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).

Conditions Studied

Triple Negative Breast Cancer

Interventions

  • DRUG Sacituzumab Govitecan-hziy (SG)

Study Locations (16)

Other

  • Seoul National University Hospital - Seoul
  • Severance Hospital, Yonsei University Health System - Seoul
  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul

Tennessee

  • West Cancer Centre - Germantown
  • SCRI Oncology Partners - Nashville
  • Tennessee Oncology, PLLC - Nashville

Queensland

  • Sunshine Coast University Private Hospital - Birtinya
  • John Flynn Private Hospital - Tugun

California

  • Los Angeles Cancer Network (LACN) - Good Sam - Los Angeles

Georgia

  • Winship Cancer Institute - Emory University - Atlanta

Kansas

  • The University of Kansas Hospital - Westwood

Missouri

  • Siteman Cancer Center - St Louis

Texas

  • Texas Oncology - DFW - Dallas

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-30
Est. Completion 2028-06
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06926920

The ClinicalTrials.gov registry entry for NCT06926920 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (59% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan-hziy (SG) is the first listed.

NCT06926920 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, Tennessee, Queensland.

Frequently Asked Questions

What is clinical trial NCT06926920 about?

NCT06926920 is a clinical study titled "A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer". The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at a...

What is the current status of trial NCT06926920?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-04-30. Estimated completion is 2028-06.

What conditions does trial NCT06926920 study?

This clinical trial studies the following conditions: Triple Negative Breast Cancer.

What interventions are being tested in trial NCT06926920?

The interventions under investigation include: Sacituzumab Govitecan-hziy (SG) (DRUG).

Who is sponsoring clinical trial NCT06926920?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06926920 being conducted?

This trial has 16 study locations across California, Georgia, Kansas, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Triple Negative Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Triple Negative Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.